Arachidonic acid-derived bioactive lipids: Their role and the role for their inhibitors in dermatology

Journal of Cutaneous Medicine and Surgery

Volumn 6, Issue 3, 2002, Pages 241-256

  Smith, Kathleen J ^a   Skelton, Henry ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE DERIVATIVE; LIPID; LIPOXIN; PROSTAGLANDIN; PROSTANOID; THROMBOXANE;

ADJUVANT THERAPY; ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CELL GROWTH; HEMOSTASIS; HUMAN; INHIBITION KINETICS; MOLECULAR MODEL; PRIORITY JOURNAL; REVIEW; SKIN DISEASE;

ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; DERMATOLOGY; DRUG DESIGN; HUMANS; LEUKOTRIENES; LIPIDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SKIN DISEASES; THROMBOXANES;

EID: 0036321976     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-001-0047-4     Document Type: Review

References (166)

1. Pharmacology of corticosteroids
2. Anti-inflammatory drugs and their mechanism of action
3. Arachidonic acid metabolism
4. Constant turnover of arachidonic acid and inhibition of a potassium current in aphsia giant neuron
5. Essential fatty acid deficiency impairs macrophage spreading and adherence. Role of arachidonate in cell adhesion
6. Unsaturated fatty acids synergistically enhance glucocorticoid induced gene expression
7. Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor alpha: Evidences for a tyrosine kinase dependent process
8. Secretory phospholipase A2 activity is required for permeability barrier homeostasis
9. Inhibition of apoptosis and prolongation of functional longevity by inflammatory mediators
10. Secretory phospholipase A2 activity is required for permeability barrier homeostasis
11. Phospholipase C-diglyceride lipase is a major pathway for arachidonic acid release in macrophages
12. Postanoid biosynthesis and mechanisms of action
13. Prostaglandin and thromboxane biosynthesis
14. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases
15. Arachidonate 15-lipoxygenase
16. A role for leukotriene antagonists in atopic dermatitis?
17. Arachidonate 5-lipoxygenase
18. Arachidonate 12-lipoxegenase
19. Leukotriene B4
20. Carboxy-substituted cinnamides: A novel series of potent oral active LTB4 receptor antagonists
21. A G-protein coupled receptor for leukotriene B4 that mediates chemotaxis
22. Identification, molecular cloning, expression, and characterization of cysteinyl leukotriene receptor
23. The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes
24. Selectivity of recombinant human leukotriene D4, Leukotriene B4, and Lipoxin A4 receptors with aspirin-triggered 15-epi-LXA4 and regulation of vascular and inflammatory responses
25. New perspectives for asthma treatment: Anti-leukotriene drugs
26. Expression and molecular cloning of human liver leukotriene B4 omega-hydroxylase (CYP4F2) gene
27. Orphan nuclear receptors: Shifting endocrinology into reverse
28. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dematitis
29. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma
30. Substance P and antigen induced release of leukotriene B4, prostaglandin D2 and histamine from guinea pig skin by different mechanisms in vitro
31. Epicutaneous application of leukotriene B4 induces patterns of tenascin and a heparin sulfate proteoglycan epitope that are typical for psoriatic lesions
32. Chemical mediators in atopic dermatitis: Involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis
33. Phospholipase A2 inhibitors and leukotriene synthesis inhibitors block TNF-induced NF activation
34. Alpha-topopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5- lipoxygenase
35. Heterogeneous distribution of lipoxygenase products in psoriatic skin lesions
36. Sphingomyelin inhibits platelet 12-lipoxygenase activity
37. Inactivation of mouse epidermal 12-lipoxygenase by anthralin-implications for the role of oxygen radicals
38. Asprin triggered 15-epilipoxin A4 stable analogs on lipoxin A4 are potent inhibitors of acute inflammation. Receptors and pathways
39. Leukotriene B4 receptor transgenic mice reveal novel protective role for lipoxins and aspirin-triggered lipoxins in reperfusion
40. A novel subgroup of class 1 G-protein coupled receptors
41. Lipoxin (LX)A4 as aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1 alpha-initiated neutrophil responses and trafficking: Regulators of cytokine-chemokine axis
42. Omega-3 fatty acids and the peroxisome
43. Endothelial derived relaxing factor reduces platelet adhesion in bovine endothelial cells
44. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
45. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid induced inflammation and indomethacin induced gastric ulceration
46. COX-1 and COX-2 inhibition: Current status and future perspective
47. Cyclooxygenase-2 as a therapeutic target
48. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells
49. Induction of cyclooxygenase by cytokines in cultured human airway smooth muscle cells: Novel inflammatory role of this cell type
50. Anti-inflammatory cyclopenterone prostaglandins are direct inhibitors of IKB kinase (IKKB)
51. Cyclopentenone prostaglandins; new allies in the war on inflammation
52. Increased production of Prostaglandin D2 in patients with sustemic mastocytosis
53. Cutaneous reactions ot intradermal prostaglandins
54. Prostaglandin D2- sensitive, sleep-promoting zone defined in the ventral surface of the rostral basal forebrain
55. Effect of prostaglandins E1 and F1 on biosynthesis of collagen
56. Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis
57. Cyclooxygenase in human and mouse skin and cultured human keratinocytes: Association of COX-2 expression with human keratinocyte differentiation
58. Enhanced pros taglandin synthesis after ultraviolet injury is mediated by endogenous histamine stimulation. A mechanism for irradiation erythema
59. Keratinocyte prostaglandin synthesis is enhanced by IL-1
60. Collagen lattice effects on fibroblast arachidonic acid metabolism
61. Cellular confluence determines injury-induced prostaglandin E2 synthesis by human keratinocyte cultures
62. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective nonsteroidal antiinflammatory drug NS-398
63. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE
64. Eicosanoids and inflammatory cells in frostbitten tissue; Prostacyclin, thromboxane, polymorphonuclear leukocytes, and mast cells
65. Suppression of interleukin 2 dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids. Evidence for a PGE independent mechanism of inhibition by the fatty acids
66. Comparison of eicosanoid generation by highly purified human Langerhans cells and keralinocytes
67. Specific NF-kappa B blockade selectively inhibits tumor necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells
68. The molecular basis of T helper 1 and T helper 2 cell differentiation
69. International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
70. Prostaglandin E receptors
71. Independent down-regulation of EP2 and EP3 subtypes of the prostaglandin E2 receptors on U937 human monocytic cells
72. More selective ligands at eicosanoid receptor subtypes improve prospects in inflammatory and cardiovascular research
73. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce calcium and cAMP signals
74. Diverse mechanisms of specificity of human receptors for eicosanoids
75. Cox-2 selective inhibitors: The new super aspirins
76. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, interferon gamma, interleukin 2, and tumor necrosis factor alpha, defining TCI (Cytotoxic T lymphocyte) and TH1 effector populations: 1 a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients
77. Selective COX-2 inhibitors and human inflammatory bowel disease
78. Interleukin 12 and Th1 responses in inflammatory bowel disease
79. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer
80. The immunopharmacology of head and neck cancer: An update
81. Prostaglandin E2 increases calcium conductance and stimulates release of substance P in avian sensory neurons
82. Prostaglandin hyperalgesia: The peripheral analgesic activity of morphine, enkephalin and opioid antagonists
83. Frostbite injuries: A rational approach based on the pathophysiology
84. Experimental and clinical observation on frostbite
85. Risk of Alzheimer's disease and duration of NSAID use
86. Natural history of erythromelalgia: Presentation and outcome in 168 patients
87. Erythromelalgia - A mysterious condition?
88. Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective inhibitors
89. Lipoxygenase mRNA in cultured human epidermal and oral keratinocytes
90. ++ binding, uptake and release
91. Effects of prostaglandin E2 on growth, morphology, morphometry and keratin pattern of bovine corneal epithelial cells cultured in vitro
92. Cyclooxygenase independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma
93. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time administration during carcinogenic process
94. Muir-Torre phenotype has a frequency of DNA mismatch repair gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria
95. Increased cyclooxygenase 2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
96. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
97. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal anti-inflammatory drugs
98. Aspirin suppresses microsatellite instability
99. Molecular pathology of cyclooxygenase-2 in neoplasia
100. Possible involvement of enchanced prostaglandin E2 production in the photosensitivity in xeroderma pigmentosum group A model mice
101. Expression of two different forms of cDNA for thromboxane synthase in insect cells and site directed mutagencsis of a critical cysteine residue
102. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
103. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines
104. Regulation of cyclo- oxygenase-2 pathway by HER2 receptor
105. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: Comparison with histopatholgical parameter
106. Resistance to apoptosis and cyclooxygenase-2 expression in human adenocarcinoma cell line HT2 CL. 19A
107. Cox-2, iNOS, and p53 as play-makers of tumor angiogenesis
108. Role of nitric oxide in growth of solid tumours: A balancing act
109. Age-associated alterations in splenic iNOS regulation: Influence of constitutively expressed IFN-gamma and correction following supplementation with PPAR alpha activators or vitamin E
110. Activators of peroxisome proliferator activated receptor gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells
111. Down regulation of peroxisome proliferator activated receptor gamma expression by inflammatory cytokines and its reversal by thazolidinediones
112. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
113. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways
114. Expression of Cyclooxygenase 2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey
115. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase 2
116. Chemopreventive activity of celecoxib a specific cyclooxygenasce 2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
117. Prostaglandin- H-synthase isozyme expression in normal and neoplastic human skin
118. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
119. p53: Radiosensitivity and anti-angiogenic effects
120. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
121. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
122. Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis
123. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice
124. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice
125. p53 gene mutations and p21 protein expression induced independently of p53, by TGF-beta and gamma-rays in squamous cell carcinoma cells
126. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
127. Synergistic effects of 13-cis retinoic acid and arachidonic acid cascade inhibitors on growth of head and neck squamous cell carcinoma in vitro
128. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes
129. Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4+, CD8+ T lymphoblasts
130. Regulation of cyclooxygenase 2 by interferon gamma and transforming growth factor alpha in normal human epidermal deratinocytes and squamous carcinoma cells. Role of mitogen activated protein kinases
131. Nonsteroidal antiinflammatory drug metabolism potentiates interferon alpha signaling by increasing STAT 1 phosphorylation
132. Phorbol ester- mediated induction of cyclooxygenase 2 gene expression in inhibited by retinoids
133. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
134. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs
135. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens
136. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth
137. Lipid hydroperoxide induced endogenous DNA adducts in hamsters: Possible mechanism of lipid hydroperoxide-mediated carcinogenesis
138. Influence of 5-lipoxygenase on in vitro growth of human mammary carcinoma cell line MCF-7
139. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs
140. 12-Lipoxygenases and 12- HETE: Role in cancer metastasis
141. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implication
142. Arachidonic acid metabolites in saliva of patients with squamous cell carcinoma of the head and neck
143. Inhibitors of lipoxygenase: A new class of cancer chemopreventive agents
144. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated drug resistance
145. In vivo effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer
146. The future potential of eicosanoids and their inhibitors in paediatric practice
147. Pharmacological manipulation of the ductus arteriosus
148. Treatment of infantile primary pulmonary hypertension by intravenous infusion of lipo-prostaglandin 12 analog
149. A multicenter blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders
150. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis
151. Aerosolized prostacyclin in adult respiratory distress syndrome
152. Acosolized prostacyclin for pulmonary hypertension in neonates
153. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre double blind placebo-controlled trial
154. Identification of non-steroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis
155. Impaired increase of prostaglandin F2 in gastric juice during steroid therapy in children
156. Femoral artery infusion of prostaglandin E1 in severe peripheral vascular disease
157. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon
158. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia
159. Successful treatment of livedo vasculitis with beraprost sodium: A possible mechanism of thrombomodulin upregulation
160. Reduction of progressive burn injury by a stable prostaglandin 12 analogue, beraprost sodium (Procylin): An experimental study in rats
161. Effect of topical application of a stable prostacyclin analogue, SM-10902 on wound healing in diabetic mice
162. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
163. Molecular pharmacology and application to the bronchial asthma of thromboxane A: Antagonists
164. Evaluation of low dose prostaglandin E1 treatment for ductus dependent congential heart disease